main aim was to reduce toxic side effects to allow drug to be used more often, more dosage and more widely for patients susceptible to the side effects all above proven so far, any improvement in efficacy over and above this would be a bonus. Removal of black box status on any of these DEP drug targets would provide new patents and set these drugs off to new sales heights. Your small throw away sentance has no merits and if anything shows you have no idea what you are invested in but good luck looks like your in regardless.
Shareholders newsletter 03/06/22, page-12
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.2¢ |
Change
-0.001(1.08%) |
Mkt cap ! $38.39M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 9.3¢ | 9.1¢ | $210.6K | 2.290M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 467139 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.4¢ | 152000 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |